- Trial Phase
- Phase 2 (Phase 3 planned but never initiated)
- Time to Market
- Unknown. The ORALTO Phase 3 trial never enrolled patients. Azurity Pharmaceuticals (private) may restart development, but no timeline exists. Prior to the sale, the ORALTO trial was expected to take ~24 months to enroll, plus regulatory review.
- Why 2/10
- MAT2203 is being sold to Azurity Pharmaceuticals as part of Matinas' exit from biotech (reverse merger with GH Power). There is no upcoming clinical or regulatory catalyst for MTNB shares related to MAT2203 — the ORALTO Phase 3 trial was never enrolled. The drug's fate now belongs to a private buyer; MTNB shareholders face a binary shareholder vote on the GH Power merger, not a drug catalyst.
MAT2203 is no longer a driver for MTNB. The company is selling the drug for $4M upfront and exiting biotech entirely via a reverse merger with GH Power (clean energy). MTNB shareholders will receive 0.1 Pubco shares per MTNB share — the stock is now a reverse-merger arbitrage play, not a biotech investment. The shareholder vote and SEC effectiveness of the registration statement (expected close by Dec 31, 2026) are the key events.
Price Chart
Executive Summary
MAT2203 is an oral, encochleated form of amphotericin B — a potent broad-spectrum antifungal typically only available intravenously. It received FDA QIDP, Fast Track, and Orphan Drug designations. The FDA agreed to a single Phase 3 registration trial (ORALTO), but the trial was never started after a licensing partnership fell through in October 2024. On July 13, 2026, Matinas BioPharma announced it is selling MAT2203 (along with its LNC platform) to private Azurity Pharmaceuticals for $4M upfront plus up to $17.5M in milestones, while simultaneously merging with GH Power to exit biotech entirely. For MTNB shareholders, MAT2203 has become a terminal asset being monetized for modest cash — the stock now tracks the reverse-merger closing, not the drug's clinical prospects.
How It Works
MAT2203 is an oral version of amphotericin B, a powerful broad-spectrum antifungal drug that is normally only available through an IV. The drug uses a lipid-crystal coating (encochleation) to protect the medicine as it passes through the stomach, allowing it to be absorbed orally and delivered to infection sites with fewer kidney and liver side effects than IV amphotericin B.
Trial Status
MAT2203 completed Phase 1 and Phase 2a studies (EnACT for cryptococcal meningitis, a Phase 2a for chronic mucocutaneous candidiasis, and compassionate-use cases). The FDA agreed on a single registrational Phase 3 trial (ORALTO) for invasive aspergillosis in mid-2024, but enrollment never started — it was contingent on a licensing partnership that fell through in October 2024. The drug is now being sold.
The Two-Sided Case
Upcoming Catalysts
- Shareholder vote on the GH Power reverse merger (expected by end of 2026)
- SEC effectiveness of the Form F-4 registration statement for the merger
- Closing of the asset sale to Azurity Pharmaceuticals (contingent on merger closing)
- Potential NYSE American delisting if merger/equity compliance not resolved
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Matinas BioPharma Holdings, Inc. 8-K MTNB ·Originating report